BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1333 related articles for article (PubMed ID: 16035057)

  • 1. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection.
    Franchello A; Ghisetti V; Marzano A; Romagnoli R; Salizzoni M
    Liver Transpl; 2005 Aug; 11(8):922-8. PubMed ID: 16035057
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term clinical and virological outcome after liver transplantation for cirrhosis caused by chronic delta hepatitis.
    Samuel D; Zignego AL; Reynes M; Feray C; Arulnaden JL; David MF; Gigou M; Bismuth A; Mathieu D; Gentilini P
    Hepatology; 1995 Feb; 21(2):333-9. PubMed ID: 7843702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lamivudine prophylaxis of liver allograft HBV reinfection in HBV related cirrhotic patients after liver transplantation.
    Lu SC; Yan LN; Li B; Wen TF; Zhao JC; Cheng NS; Liu C; Liu J; Wang XB; Li XD; Qin S; Zhao LS; Lei BJ; Zhang XH
    Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):26-32. PubMed ID: 14969833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transmission of hepatitis B infection from hepatitis B core antibody--positive liver allografts is prevented by lamivudine therapy.
    Yu AS; Vierling JM; Colquhoun SD; Arnaout WS; Chan CK; Khanafshar E; Geller SA; Nichols WS; Fong TL
    Liver Transpl; 2001 Jun; 7(6):513-7. PubMed ID: 11443579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts.
    Vizzini G; Gruttadauria S; Volpes R; D'Antoni A; Pietrosi G; Filì D; Petridis I; Pagano D; Tuzzolino F; Santonocito MM; Gridelli B
    Clin Transplant; 2011; 25(1):E77-81. PubMed ID: 21039887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].
    Yang Y; Yang Y; Zhang J; Yi HM; Lu MQ; Cai CJ; Li X; Jiang N; Xu C; Li H; Wang GS; Yi SH; Zhang JF; Jiang H; Yang Q; Chen GH
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Oct; 28(10):1810-2. PubMed ID: 18971179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance.
    Ghisetti V; Marzano A; Zamboni F; Barbui A; Franchello A; Gaia S; Marchiaro G; Salizzoni M; Rizzetto M
    Liver Transpl; 2004 Mar; 10(3):356-62. PubMed ID: 15004761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver transplantation in European patients with the hepatitis B surface antigen.
    Samuel D; Muller R; Alexander G; Fassati L; Ducot B; Benhamou JP; Bismuth H
    N Engl J Med; 1993 Dec; 329(25):1842-7. PubMed ID: 8247035
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver transplantation in delta virus infection.
    Roche B; Samuel D
    Semin Liver Dis; 2012 Aug; 32(3):245-55. PubMed ID: 22932973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical significance of hepatitis D virus co-infection in patients with chronic hepatitis B in Korea.
    Kim HS; Kim SJ; Park HW; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK
    J Med Virol; 2011 Jul; 83(7):1172-7. PubMed ID: 21541950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term lamivudine monotherapy prevents development of hepatitis B virus infection in hepatitis B surface-antigen negative liver transplant recipients from hepatitis B core-antibody-positive donors.
    Prakoso E; Strasser SI; Koorey DJ; Verran D; McCaughan GW
    Clin Transplant; 2006; 20(3):369-73. PubMed ID: 16824156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis B virus reactivation and efficacy of prophylaxis with lamivudine in patients undergoing allogeneic stem cell transplantation.
    Giaccone L; Festuccia M; Marengo A; Resta I; Sorasio R; Pittaluga F; Fiore F; Boccadoro M; Rizzetto M; Bruno B; Marzano A
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):809-17. PubMed ID: 20060484
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Course of a HBsAg positive liver transplantation in a hepatitis B and D virus coinfected recipient.
    Bahde R; Hölzen JP; Wolters HH; Schmidt HH; Bock CT; Lügering A; Spieker T; Senninger N; Brockmann JG
    Ann Hepatol; 2011; 10(3):355-60. PubMed ID: 21677340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical impact and efficacy of lamivudine therapy in de novo hepatitis B infection after liver transplantation.
    Castells L; Vargas V; Rodríguez F; Allende H; Buti M; Sánchez-Avila JF; Jardí R; Margarit C; Pumarola T; Esteban R; Guardia J
    Liver Transpl; 2002 Oct; 8(10):892-900. PubMed ID: 12360430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.
    Yang Y; Zhang Q; Cai CJ; Lu MQ; Li X; Jiang N; Jiang H; Xu C; Li H; Wang GS; Yi SH; Zhang J; Zhang JF; Yi HM; Zhang YC; Chen GH
    Chin Med J (Engl); 2007 Aug; 120(16):1400-3. PubMed ID: 17825167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
    Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
    World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins.
    Roche B; Roque-Afonso AM; Sebagh M; Delvart V; Duclos-Vallee JC; Castaing D; Samuel D
    Liver Transpl; 2010 Jul; 16(7):885-94. PubMed ID: 20583085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minimization of anti-hepatitis B surface antigen immunoglobulins for prophylaxis of hepatitis B viral recurrence in the first month after liver transplantation: the meaning of HBsAg quantitative level at the time of transplant.
    Tandoi F; Nada E; Pittaluga F; Fop F; Lupo F; Romagnoli R; Salizzoni M
    Transplant Proc; 2014 Sep; 46(7):2308-11. PubMed ID: 25242775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-titer antibody to hepatitis B surface antigen before liver transplantation can prevent de novo hepatitis B infection.
    Su WJ; Ho MC; Ni YH; Chen HL; Hu RH; Wu YM; Chang MH; Lee PH
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):203-8. PubMed ID: 19179883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation.
    Fung J; Cheung C; Chan SC; Yuen MF; Chok KS; Sharr W; Dai WC; Chan AC; Cheung TT; Tsang S; Lam B; Lai CL; Lo CM
    Gastroenterology; 2011 Oct; 141(4):1212-9. PubMed ID: 21762659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.